Patients with AML-MRC that is non-MDS mediated have worse outcomes, independent of age and cytogenetics, but at least in part related to molecular mutations in diverse tumor suppressor genes such as TP53 [93]. The gene discussed is TP53; the disease is acute myeloid leukemia.